Dublin, March 30, 2026 (GLOBE NEWSWIRE) — The “Uveal Neoplasms Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The global uveal neoplasms market has demonstrated robust growth, with projections indicating a rise from $1.14 billion in 2025 to $1.2 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This upward trend is primarily due to advancements in ophthalmic diagnostic tools, expansion of specialized eye care centers, heightened awareness of ocular tumors, and the availability of radiation-based therapies.
Further growth is anticipated, with the market expected to reach $1.5 billion by 2030, at a CAGR of 5.6%. Key drivers in this forecast include increased adoption of precision medicine, heightened investment in ocular oncology research, and expanded use of immunotherapy and advanced imaging diagnostics. Trends suggest a growing emphasis on targeted treatments, early tumor detection, and personalized treatment regimens.
The rising incidence of eye cancer significantly propels market growth. Uveal neoplasms, notably uveal melanoma, pose serious health risks due to their potential to metastasize, particularly to the liver. Factors like better detection methods, environmental exposure, and aging populations contribute to the increased incidence. Data from Cancer Research UK highlights a 50% projected rise in eye cancer rates in the UK from 2023-2038, reaching 3 cases per 100,000 annually by 2038.
Major industry players are concentrating on liver-directed therapies, such as percutaneous hepatic perfusion (PHP), to improve localized tumor control while minimizing systemic toxicity. In August 2023, Delcath Systems, Inc. received FDA approval for HEPZATO KIT, a PHP-based therapy for metastatic uveal melanoma, demonstrating significant tumor response and disease control. This allows for higher localized drug concentration with reduced systemic exposure.
Strategic mergers, such as the one between TriSalus Life Sciences and MedTech Acquisition Corporation in August 2023, are expected to enhance treatment platforms for liver and pancreatic cancers. This merger aims to drive technological advancements, sales growth, and secure funding for key initiatives.
Leading companies in this market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., along with others like IDEAYA Biosciences and Bristol-Myers Squibb. North America is currently the largest region in the uveal neoplasms market, with global coverage extending to Asia-Pacific, Europe, and other regions.
Reasons to Purchase:
- Attain a global perspective with coverage across 16 geographies.
- Evaluate the impact of macro factors like geopolitical tensions, trade policies, and regulatory landscapes.
- Formulate regional strategies using localized data.
- Pinpoint investment-worthy growth segments.
- Surpass competitors by leveraging forecast data and market trends.
- Understand customer nuances through end-user analysis.
- Compare performance with competitors using market share, innovation, and brand analysis.
- Assess market potential with total addressable market (TAM) and market attractiveness scoring.
- Utilize reliable data for both internal and external presentations.
- Receive updated data alongside an Excel dashboard for effortless analysis.
Report Scope
Markets Covered:
1) By Treatment Type: Drugs; Therapy
2) By Route Of Administration: Oral; Injectable; Other Route Administration
3) By Distribution Channel: Hospitals Pharmacies; Online Pharmacies; Retail Pharmacies
Subsegments:
1) By Drugs: Chemotherapeutic Agents; Targeted Therapy Drugs; Immunotherapy Drugs
2) By Therapy: Radiation Therapy; Laser Therapy; Photodynamic Therapy
Companies Mentioned: Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., IDEAYA Biosciences Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, and more.
Countries: Australia, Brazil, China, France, Germany, and others.
Regions: Asia-Pacific, South East Asia, Western Europe, North America, and more.
Time Series: Includes five-year historic data and ten-year forecasts.
Data Segmentation: Comprehensive data on country and regional market segments, growth ratios, and competitor shares.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $1.2 Billion |
| Forecasted Market Value (USD) by 2030 | $1.5 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
The companies featured in this Uveal Neoplasms market report include:
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- IDEAYA Biosciences Inc.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Novartis AG
- Eli Lilly and Company
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- Verastem Oncology Inc.
- Iovance Biotherapeutics Inc.
- Immunocore Holdings PLC
- Aura Biosciences
- Foghorn Therapeutics Inc.
- Syncona Limited
- iOnctura SA
- Linnaeus Therapeutics, Inc.
- Delcath Systems Inc
- Bellicum Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/r/8s4jfl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
